Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

BACKGROUND/AIMS: The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Newell, Pippa, Toffanin, Sara, Villanueva, Augusto, Chiang, Derek Y., Minguez, Beatriz, Cabellos, Laia, Savic, Radoslav, Hoshida, Yujin, Lim, Kiat Hon, Melgar-Lesmes, Pedro, Yea, Steven, Peix, Judit, Deniz, Kemal, Fiel, M. Isabel, Thung, Swan, Alsinet, Clara, Tovar, Victoria, Mazzaferro, Vincenzo, Bruix, Jordi, Roayaie, Sasan, Schwartz, Myron, Friedman, Scott L., Llovet, Josep M.
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2970800/
https://ncbi.nlm.nih.gov/pubmed/19665249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2009.03.028
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares